Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK

PharmacoEconomics

Volumn 24, Issue 1, 2006, Pages 67-79

  McEwan, Phil ^a,e   Dixon, Simon ^b   Baboolal, Keshwar ^c   Conway, Pete ^d   Currie, Craig J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d PFIZER INC   (United States)

^e Cardiff Research Consortium   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALFACALCIDOL; ATENOLOL; AZATHIOPRINE; CALCIUM CARBONATE; CORTICOSTEROID; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; DOXAZOSIN; ERYTHROPOIETIN; FERROUS SULFATE; GANCICLOVIR; LISINOPRIL; LOSARTAN; METHYLPREDNISOLONE; NIFEDIPINE; OKT 3; OMEPRAZOLE; PREDNISOLONE; RAPAMYCIN; SIMVASTATIN; TACROLIMUS;

ALTERNATIVE MEDICINE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DRUG COST; DRUG UTILIZATION; GRAFT REJECTION; GRAFT SURVIVAL; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SIMULATION; STATISTICAL ANALYSIS; SURVIVAL; UNITED KINGDOM;

ADULT; COST-BENEFIT ANALYSIS; FEMALE; GRAFT REJECTION; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; SIROLIMUS; TACROLIMUS;

EID: 32044438904     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624010-00006     Document Type: Article

References (35)

1. Irish W, Sherrill B, Brennan DC, et al. Three-year post transplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. Transplantation 2003; 76: 1686-90
2. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834-41
3. Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003; 14: 2980-4
4. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus pricyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75: 2048-53
5. Jurewicz WA. Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003; 18 Suppl. 1: i7-11
6. Bunnapradist S, Daswani A, Takemoto SK. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. Transplantation 2003; 76: 10-5
7. Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant 1999; 13: 209-20
8. Podbielski J, Schoenberg L. Use of sirolimus in kidney transplantation. Prog Transplant 2001; 11: 29-32
9. Morelon E, Mamzer-Bruneel MF, Peraldi MN, et al. Sirolimus: a new promising immunosuppressive drug: towards a rationale for its use in renal transplantation. Nephrol Dial Transplant 2001; 16: 18-20
10. National Institute for Health and Clinical Excellence. NICE guidelines on renal transplant immunosuppression [online]. Available from URL: http://www.nice.org.uk/page.aspx?.o=221103 [Accessed 2005 Jun 15]
11. National Kidney Federation. Transplantation and live donors [online]. Available from URL: http://www.kidney.org.uk/campaigns/Transplantation/ukt- press-dec03.html [Accessed 2005 Oct 27]
12. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217-27
13. Karnon J. Alternative decision modelling techniques for the evaluation of health care technologies: markov processes versus discrete event simulation. Health Econ 2003; 12: 837-48
14. Gentil MA, Cantarell Aixendri C, Gonzalez Roncero FM, et al. Impact of the new drugs in the cost of maintenance immunosuppression of renal transplantation: is it justified? Nephrol Dial Transplant 2004; 19 Suppl. 3: III77-82
15. Gonzalez Molina M, Sola E, Cabello M, et al. Effect of the immunosuppressive treatment on long-term renal graft survival. Nephrol Dial Transplant 2004; 19 Suppl. 3: III52-56
16. Douglas R. Department of Health (UK). Discount rates and the cost of capital -EL (97) 71 [online]. Available from URL: http://www.dh.gov.uk// assetRoot/04/01/13/61/04011361.pdf [Accessed 2005 Jun 18]
17. West RR, McNabb R, Thompson AG, et al. Estimating implied rates of discounting in health care decision making. Health Technol Assess 2003; 7: 1-60
18. McEwan P, Keshwar B, Dixon S, et al. Patterns of graft and patient survival following renal transplantation and evaluation of serum creatinine as a predictor of survival: a review of data collected from one clinical centre over 34 years. Curr Med Res Opin 2005; 21 (11): 1793-1800
19. Oberbauer R, Kreis H, Johnson RW, et al. Rapamune Maintenance Regimen Study Group. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364-70
20. Rogers J, Ashcraft EE, Emovon OE, et al. Long-term outcome of sirolimus rescue in kidney-pancreas transplantation. Transplantation 2004; 78: 619-22
21. Kiberd BA. Should hepatitis C-infected kidneys be transplanted in the United States? Transplantation 1994; 57: 1068-72
22. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost utility of renal transplantation. Kidney Int 1996; 50: 235-42
23. Gudex CM. Health-related quality of life in end-stage renal failure. Qual Life Res 1995; 4: 359-66
24. Department of Health. NHS costing manual: detailed guide to costing for NHS providers and commissioners [online]. Available from URL: http://www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/FinanceAndPlanning/ NHSCostingManual/fs/en [Accessed 2004 May 1]
25. British National Formulary [online]. Available from URL: www.bnf.org. [Accessed 2004 May 1]
26. Parlevliet KJ, ten Berge RJ, Raasveld MH, et al. Low-dose OKT3 induction therapy following renal transplantation: a controlled study. Nephrol Dial Transplant 1994; 9: 698-703
27. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-8
28. Friedman PJ. Serum creatinine: an independent predictor of survival after stroke. J Intern Med 1991; 229: 175-9
29. Ferrara JJ, Wanamaker S, Carey LC. Preoperative serum creatinine as a predictor of survival in perforated gastroduodenal ulcer. Am Surg 1985; 51: 551-5
30. Carter JT, Lee CM, Weinstein RJ, et al. Evaluation of the older cadaveric kidney donor: the impact of donor hypertension and creatinine clearance on graft performance and survival. Transplantation 2000; 70: 765-71
31. Cecka JM. Outcome statistics of renal transplants with an emphasis on long-term survival. Clin Transplant 1994; 8: 324-7
32. Flechner SM, Modlin CS, Serrano DP, et al. Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. Transplantation 1996; 62: 1235-41
33. Zuckermann A, Ploner M, Czerny M, et al. Even slightly impaired kidney function (creatinine >1.79 MMOL/L) one year after cardiac transplantation has a negative impact on long term survival. J Heart Lung Transplant 2001; 20: 206
34. Laskow DA, Neylan JF, Shapiro RS, et al. The role of tacrolimus in adult kidney transplantation: a review. Clin Transplant 1998; 12: 489-503
35. Gordois A, Mudge M, Davey P, et al. The cost-effectiveness of sirolimus with cyclosporin withdrawal versus low dose sirolimus and continued cyclosporin when initiated within four months of renal transplantation [abstract]. Value Health 2004; 7: 364